Bharat Book Presents: China Genetic Engineering Drug Industry Report, 2011-2012 – Video

Posted: January 5, 2013 at 1:42 pm

|


Video Link: https://www.youtube.com/watch?v=QZb0j7xIb40



Bharat Book Presents: China Genetic Engineering Drug Industry Report, 2011-2012
For more information kindly visit on: http://www.bharatbook.com China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs. In recent years, the compound growth rate of genetic engineering drug market in China is as high as 49%, with an average gross margin of more than 80%. However, the technology strength and efficacy of locally produced genetic engineering drugs are relatively weak. In particular, the pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) for injection of CSPC Pharmaceutical Group Limited that approved for marketing in March 2012 is the only homemade long-acting protein product. Still, due to the impetus of huge market capacity as well as a package of preferential policies, many domestic enterprises, including GeneScience Pharmaceuticals, Amoytop and Anhui Anke Biotechnology, are accelerating the industrialized research of long-acting protein drugs. Monoclonal antibody is one of the most promising genetic engineering drugs. As of May 2012, SFDA approved the marketing of a total of 18 monoclonal antibody drugs. Among these drugs, nearly 60% are foreign brands including Roche, Merck and Novartis with the combined sales accounting for three fourths of the Chinese monoclonal antibody drug market. However, with the marketing of monoclonal antibody drugs made by companies such as Shanghai CP Guojian ...

By: Deepa Kamath

The rest is here:
Bharat Book Presents: China Genetic Engineering Drug Industry Report, 2011-2012 - Video

Related Posts

Comments are closed.

Categories
Bookmarks
Archives

Copyright © 2009 Genetherapy Genetic Medicine